Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

(2019) Vicky Makker et al.   LANCET ONCOLOGY

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

(2018) Johanna C. Bendell et al.   CLINICAL CANCER RESEARCH

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

(2018) Benjamin D. Hopkins et al.   NATURE

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

(2016) Vicky Makker et al.   CANCER

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

(2016) Josep María del Campo et al.   GYNECOLOGIC ONCOLOGY

Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth

(2016) M. C. Smith et al.   MOLECULAR CANCER THERAPEUTICS

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

(2015) Ursula Matulonis et al.   GYNECOLOGIC ONCOLOGY

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

(2015) Donavan T. Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Obesity and cancer, a case for insulin signaling

(2015) Y Poloz et al.   Cell Death & Disease

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

(2014) Dejan Juric et al.   NATURE

New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway--The Devil Is in the Details

(2013) A. P. Myers   CLINICAL CANCER RESEARCH

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Overexpression of the Insulin Receptor Isoform A Promotes Endometrial Carcinoma Cell Growth

(2013) Chun-Fang Wang et al.   PLoS One

Insulin resistance: A significant risk factor of endometrial cancer

(2012) Nan Mu et al.   GYNECOLOGIC ONCOLOGY

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study

(2012) Olivier Trédan et al.   Targeted Oncology

Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer

(2011) Mats Lambe et al.   CANCER CAUSES & CONTROL

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

(2011) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group

(2008) Agustin A. Garcia et al.   GYNECOLOGIC ONCOLOGY